سعر ليفيديميا 2 مجم 30 قرص 2024

Lividemia 2 mg (Western Pharmaceutical Industries, Egypt): pitavastatin 2 mg tablets, pack of 30; an HMG-CoA reductase inhibitor (statin) used with diet to lower LDL cholesterol.

• Adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Adjunct to diet to reduce LDL-C in adults and children aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).Population: Adults and children >= 8 yearsDailyMed (U.S. National Library of Medicine)

• Most frequent adverse reactions (>= 2%): myalgia, constipation, diarrhoea, back pain and pain in extremity.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Concomitant use of cyclosporine.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Acute liver failure or decompensated cirrhosis.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to pitavastatin or any excipient (angioedema, rash, pruritus and urticaria have been reported).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Myopathy and rhabdomyolysis: risk increases with age 65 or older, uncontrolled hypothyroidism, renal impairment, certain interacting drugs and higher doses; discontinue if CK is markedly elevated or myopathy is suspected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Immune-mediated necrotizing myopathy has been reported rarely; discontinue if suspected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hepatic dysfunction: transaminase increases and rare hepatic failure; consider liver enzyme testing before starting and as clinically indicated.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• CyclosporineSignificantly increases pitavastatin exposure and myopathy risk; contraindicated.DailyMed (U.S. National Library of Medicine)
• GemfibrozilIncreased risk of myopathy/rhabdomyolysis; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
• ErythromycinSignificantly increases pitavastatin exposure; do not exceed 1 mg once daily.DailyMed (U.S. National Library of Medicine)

• Discontinue when pregnancy is recognised (or consider ongoing therapeutic need); may cause fetal harm based on mechanism, although observational statin data have not identified a risk of major congenital malformations.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Breastfeeding is not recommended during treatment.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Pitavastatin: Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme of cholesterol biosynthesis, lowering hepatic cholesterol and LDL-C (US LIVALO label).